| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8830396 | Urology Practice | 2017 | 24 Pages |
Abstract
Percutaneous ablation has become the most common ablative modality for early stage kidney cancer. Although percutaneous ablation carries a more favorable safety profile, posttreatment morbidity occurs with some frequency, highlighting the need for continued urologist engagement.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Andrew T. Lenis, Hung-Jui Tan, Joshua A. Halpern, Aaron A. Laviana, Brian Shuch, Jim C. Hu,